Novo Nordisk Is Losing Its Lead To Eli Lilly In The Obesity Drug War. Here’s What Went Wrong.
About this episode
This episode discusses the competition between Novo Nordisk and Eli Lilly in the obesity drug market and the factors leading to Novo Nordisk's decline.
On this episode of Growth Stories, we take a look at the escalating rivalry between Novo Nordisk and Eli Lilly and how the Danish drugmaker lost its grip on the weight-loss drug market.
Topics covered
- obesity drugs
- pharmaceutical rivalry
- weight-loss market
- Novo Nordisk
- Eli Lilly
Keywords
- Novo Nordisk
- Eli Lilly
- obesity drugs
- weight-loss
- pharmaceutical competition
Mentioned in this episode
Organizations: Novo Nordisk, Eli Lilly
Places: Denmark
More episodes of Growth Stories With IBD
- SpaceX IPO: Inside Elon Musk's $1.75 Trillion Bet On Rockets, Satellites And AI
- How This Uranium Enrichment Technology Aims To Solve The Nuclear Fuel Bottleneck For Big Tech
- Rare Earth Race: Why The U.S. Is Paying Billions To Break China’s Mineral Monopoly
- Why The Next Big AI Concern Runs Through Main Street
- Nano Nuclear Energy Has Surged 650% Since Its Public Debut. CEO Says Growth Is Just Getting Started.
- Netflix's Trillion-Dollar Quest: Inside The Streamer's Bold Bet On Future Growth
Explore listener stats, chart rankings, contacts and more on the Growth Stories With IBD podcast page.